Altimmune, Inc. Insider Trading

ALT

⊜ Compare

Last 12 months

Insiders bought 370K on the open market and sold nothing.

Net open-market

+370K

11 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

6 / 0

executives and directors

Last open-market buy

Aug 2026

Aug 13, 2026

Get an email when ALT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 13	Jerome Benedict Durso President and CEO	Bought	15,000	$2.95	44K	32%	Form 4
Apr 6	John Gill Director	Bought	9,200	$3.41	31K	74%	Form 4
Apr 1	Jerome Benedict Durso President and CEO	Bought	15,000	$3.14	47K	46%	Form 4
Apr 1	Gregory L Weaver Chief Financial Officer	Bought	10,000	$3.15	32K	36%	Form 4
Mar 6	Jerome Benedict Durso President and CEO	Bought	20,000	$3.54	71K	160%	Form 4
Mar 6	Gregory L Weaver Chief Financial Officer	Bought	5,000	$3.54	18K	22%	Form 4
Jan 8	Wayne Pisano Director	Bought	5,000	$4.08	20K	59%	Form 4
Jan 5	Catherine A. Sohn Director	Bought	500	$4.24	2K	50%	Form 4
Dec 29, 2025	Diane Jorkasky Director	Bought	527	$3.80	2K	New	Form 4
Dec 23, 2025	John Gill Director	Bought	12,500	$4.10	51K	New	Form 4
Dec 22, 2025	Jerome Benedict Durso Director	Bought	12,500	$4.13	52K	New	Form 4
Mar 17, 2025	Catherine A. Sohn Director	Bought	1,000	$5.78	6K	New	Form 4
Mar 13, 2025	Gregory L Weaver Chief Financial Officer	Bought	10,000	$5.20	52K	New	Form 4

Aug 13
Jerome Benedict Durso
President and CEO · bought 15,000 at $2.95
44K
32% of stake
Apr 6
John Gill
Director · bought 9,200 at $3.41
31K
74% of stake
Apr 1
Jerome Benedict Durso
President and CEO · bought 15,000 at $3.14
47K
46% of stake
Apr 1
Gregory L Weaver
Chief Financial Officer · bought 10,000 at $3.15
32K
36% of stake
Mar 6
Jerome Benedict Durso
President and CEO · bought 20,000 at $3.54
71K
160% of stake
Mar 6
Gregory L Weaver
Chief Financial Officer · bought 5,000 at $3.54
18K
22% of stake
Jan 8
Wayne Pisano
Director · bought 5,000 at $4.08
20K
59% of stake
Jan 5
Catherine A. Sohn
Director · bought 500 at $4.24
2K
50% of stake
Dec 29, 2025
Diane Jorkasky
Director · bought 527 at $3.80
2K
New position
Dec 23, 2025
John Gill
Director · bought 12,500 at $4.10
51K
New position
Dec 22, 2025
Jerome Benedict Durso
Director · bought 12,500 at $4.13
52K
New position
Mar 17, 2025
Catherine A. Sohn
Director · bought 1,000 at $5.78
6K
New position
Mar 13, 2025
Gregory L Weaver
Chief Financial Officer · bought 10,000 at $5.20
52K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ALT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ALT

CompareIntrinsic value

NTHINeonC Technologies Holdings

$3.17+3.26%10

GRDXGridAI Technologies Corp.

$5.43+12.42%0

IBOImpact Biomedical Inc.

$4.10+1.99%20

LYELLyell Immunopharma, Inc.

$15.43+43.27%10

OWPCOne World Products Inc.

$0.00+0.00%46

BDPTBioadaptives Inc.

$0.00-5.88%25

AVTXAvalo Therapeutics Inc.

$7.07-2.48%10

JUNSJupiter Neurosciences Inc.

$2.46+1.23%10

Held by ETFs

ALT is in 17 US ETFs. The largest of them, with ALT's weight in each:

Spot a number that looks wrong? Check it in ALT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ALT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.